BRPI0608259A2 - uso de oligodesoxírribonucleotídeos - Google Patents

uso de oligodesoxírribonucleotídeos

Info

Publication number: BRPI0608259A2
Authority: BR; Brazil
Prior art keywords: oligodeoxyribonucleotides; tumors; produced; oligotide; defibrotide
Prior art date: 2005-03-03

Application number

BRPI0608259A

Other languages

English (en)

Inventor

Günther Eissner

Laura Iris Ferro

Massimo Iacobelli

Original Assignee

Gentium Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-03

Filing date

2006-02-27

Publication date

2016-10-11

2006-02-27 Application filed by Gentium Spa filed Critical Gentium Spa

2006-02-27 Priority claimed from PCT/EP2006/060306 external-priority patent/WO2006094917A2/en

2016-10-11 Publication of BRPI0608259A2 publication Critical patent/BRPI0608259A2/pt

Links

229940124276 oligodeoxyribonucleotide Drugs 0.000 title abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 2
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
208000034578 Multiple myelomas Diseases 0.000 abstract 1
206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 abstract 1
230000033115 angiogenesis Effects 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
201000008275 breast carcinoma Diseases 0.000 abstract 1
229960004120 defibrotide Drugs 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
238000000605 extraction Methods 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
229960002930 sirolimus Drugs 0.000 abstract 1
235000013311 vegetables Nutrition 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

BRPI0608259A 2005-03-03 2006-02-27 uso de oligodesoxírribonucleotídeos BRPI0608259A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IT000336A ITMI20050336A1 (it)	2005-03-03	2005-03-03	Formulazione ad attivita' anti-tumorale
US73140405P	2005-10-28	2005-10-28
PCT/EP2006/060306 WO2006094917A2 (en)	2005-03-03	2006-02-27	Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors

Publications (1)

Publication Number	Publication Date
BRPI0608259A2 true BRPI0608259A2 (pt)	2016-10-11

Family

ID=39085989

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BRPI0607833A BRPI0607833A2 (pt)	2005-03-03	2006-02-27	uso de defibrotídeo e/ou oligodesoxirribonucleotídeos
BRPI0608259A BRPI0608259A2 (pt)	2005-03-03	2006-02-27	uso de oligodesoxírribonucleotídeos

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
BRPI0607833A BRPI0607833A2 (pt)	2005-03-03	2006-02-27	uso de defibrotídeo e/ou oligodesoxirribonucleotídeos

Country Status (9)

Country	Link
EP (1)	EP1867335B1 (pt)
CN (3)	CN101123973A (pt)
AT (1)	ATE514427T1 (pt)
BR (2)	BRPI0607833A2 (pt)
DK (1)	DK1867335T3 (pt)
ES (1)	ES2366486T3 (pt)
IT (1)	ITMI20050336A1 (pt)
PT (1)	PT1867335E (pt)
ZA (1)	ZA200707417B (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1252174B (it)	1991-12-09	1995-06-05	Crinos Industria Farmaco	Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
AU754242B2 (en) *	1997-04-28	2002-11-07	Arsinur Burcoglu	Method of treating HIV infection and related secondary infections thereof
WO1998054313A2 (en) *	1997-05-30	1998-12-03	Mcgill University	Dna methyltransferase genomic sequences and antisense oligonucleotides
DE19740384A1 (de) *	1997-09-08	1999-03-11	Max Delbrueck Centrum	Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN

2005
- 2005-03-03 IT IT000336A patent/ITMI20050336A1/it unknown
2006
- 2006-02-27 BR BRPI0607833A patent/BRPI0607833A2/pt not_active IP Right Cessation
- 2006-02-27 ES ES07117228T patent/ES2366486T3/es not_active Expired - Lifetime
- 2006-02-27 CN CNA2006800055559A patent/CN101123973A/zh active Pending
- 2006-02-27 CN CNA2008100822369A patent/CN101254204A/zh active Pending
- 2006-02-27 DK DK07117228.2T patent/DK1867335T3/da active
- 2006-02-27 PT PT07117228T patent/PT1867335E/pt unknown
- 2006-02-27 BR BRPI0608259A patent/BRPI0608259A2/pt not_active IP Right Cessation
- 2006-02-27 AT AT07117228T patent/ATE514427T1/de active
- 2006-02-27 EP EP07117228A patent/EP1867335B1/en not_active Expired - Lifetime
- 2006-02-27 CN CNA2006800065739A patent/CN101232892A/zh active Pending
- 2006-02-27 ZA ZA200707417A patent/ZA200707417B/xx unknown

Also Published As

Publication number	Publication date
CN101254204A (zh)	2008-09-03
PT1867335E (pt)	2011-09-06
CN101232892A (zh)	2008-07-30
EP1867335A2 (en)	2007-12-19
EP1867335B1 (en)	2011-06-29
ATE514427T1 (de)	2011-07-15
ITMI20050336A1 (it)	2006-09-04
DK1867335T3 (da)	2011-08-01
BRPI0607833A2 (pt)	2017-05-30
ZA200707417B (en)	2008-12-31
CN101123973A (zh)	2008-02-13
ES2366486T3 (es)	2011-10-20
EP1867335A3 (en)	2008-03-12

Similar Documents

Publication	Publication Date	Title
CY1125550T1 (el)	2026-02-25	Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
DOP2011000199A (es)	2011-10-15	Compuestos heterociclocos y metodos de uso
EA200901074A1 (ru)	2010-04-30	Лечение метастатической стадии рака предстательной железы дегареликсом
ATE519508T1 (de)	2011-08-15	Medizinische ballons
MX346924B (es)	2017-04-05	Compuestos de diarilhidantoina.
ECSP105178A (es)	2010-03-31	Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
DOP2011000198A (es)	2012-08-31	Compuestos y metodos de uso
ATE518559T1 (de)	2011-08-15	Mikrobearbeitete medizinprodukte
MX361467B (es)	2018-12-06	Compuestos de isoindolina para uso en el tratamiento de cancer.
PT2518509E (pt)	2014-09-01	Diagnóstico molecular e classificação de melanoma maligno com base em marcadores seleccionados da listagem que consiste em rgs1, ncoa3, spp1, phip
MX2010009670A (es)	2010-09-22	Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
ATE492651T1 (de)	2011-01-15	Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs
EA201270606A1 (ru)	2013-01-30	Новое противоопухолевое применение кабазитаксела
ECSP11011021A (es)	2011-06-30	Antagonistas de la via hedgehog de ftalazina disustituida
CL2007002951A1 (es)	2008-02-01	Uso de compuestos derivados de espiroheterociclicos en el tratamiento de hipercolesterolemia, hiperplasia benigna de prostata, pruritis, cancer.
WO2006094917A8 (en)	2008-01-31	Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors
WO2007100920A3 (en)	2007-12-21	Diagnosis and treatment of prostate cancer
ATE527998T1 (de)	2011-10-15	Illudin-analoga als krebsmittel
WO2009047568A3 (en)	2009-07-23	In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells
WO2009105457A3 (en)	2009-12-30	Slit2 cancer markers
WO2006113483A3 (en)	2007-05-31	Methods and compositions for treating or preventing cancer
WO2007056049A3 (en)	2008-01-31	Molecular profiling of cancer
EP2298074A3 (en)	2011-10-26	Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
WO2007033167A3 (en)	2007-10-18	Compositions and methods for detecting and treating cancer
BRPI0608259A2 (pt)	2016-10-11	uso de oligodesoxírribonucleotídeos

Legal Events

Date	Code	Title	Description
2010-08-24	B06G	Technical and formal requirements: other requirements [chapter 6.7 patent gazette]	Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.
2011-10-18	B11Z	Dismissal: petition dismissal - article 216, par 2 of industrial property law	Free format text: REFERENTE A PETICAO 020070122625/RJ DE 31/08/2007.
2016-09-27	B11M	Decision cancelled [chapter 11.13 patent gazette]	Free format text: O DESPACHO 11.6.1 DA RPI 2128 DE 18/10/2011 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.
2016-10-04	B06H	Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]	Free format text: O DESPACHO 6.7 DA RPI 2068 DE 24/08/2010 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.
2017-02-07	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2017-05-30	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
2021-06-08	B350	Update of information on the portal [chapter 15.35 patent gazette]